SB 24-060

Senate Bill 24-060, which has been signed into law, ensures that the Colorado Prescription Drug Affordability Review Board cannot review or set price limits for drugs designated as treatments for rare diseases by the FDA. This means that expensive medications used to treat uncommon illnesses will not face affordability checks in Colorado, potentially keeping their prices high but ensuring patients have access to these specialized treatments. The bill is now law and affects how the state manages drug costs for rare disease treatments.

Official Summary

The bill states that the Colorado prescription drug affordability review board has no authority to perform an affordability review of, or to establish an upper payment limit for, any prescription drug that is designated as a drug for a rare disease or condition by the federal food and drug administration. (Note: This summary applies to this bill as introduced.)